Related Experiment Video

Updated: Jun 18, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

The polyamine transport system as a target for anticancer drug development

Andrew J Palmer1, Heather M Wallace

  • 1Division of Applied Medicine, School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK.

Amino Acids
|December 4, 2009
PubMed

Insights

Targeting cancer cells specifically is challenging due to drug toxicity and tumor complexity. This review explores using the polyamine pathway for selective anticancer drug delivery, offering a promising alternative.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Current anticancer drugs often cause systemic toxicity due to non-specific side effects.
  • Targeting single pathways in cancer is insufficient for a cure due to pathway redundancy.
  • The polyamine pathway presents a potential target for novel anticancer strategies.

Purpose of the Study:

  • To review the polyamine pathway as a target for anticancer drug development.
  • To explore the exploitation of the polyamine transport system for selective cancer drug delivery.

Main Methods:

  • Literature review of the polyamine pathway and its role in cancer.
  • Analysis of the polyamine transport system's properties.
  • Discussion of potential applications in drug delivery systems.

Main Results:

  • The polyamine pathway has historically been a target for anticancer agent development.
  • The polyamine transport system exhibits characteristics amenable to targeted drug delivery.
  • Exploiting this system could lead to novel, selective anticancer therapies.

Conclusions:

  • The polyamine pathway offers a viable target for developing new anticancer drugs.
  • The polyamine transport system's selectivity can be leveraged for targeted drug delivery.
  • This approach holds promise for improving the efficacy and reducing the toxicity of cancer treatments.

More Related Videos

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.